# PolyPeptide Laboratories, Inc. - Inspection Records

Source: https://www.keypedia.com/companies/polypeptide-laboratories-inc/9d05664c-4a42-45cc-81f6-ef85c356ecc1

> Inspection records and compliance data for PolyPeptide Laboratories, Inc. in Torrance, California. Access full analysis and detailed observations.

---

## Details

- Name: PolyPeptide Laboratories, Inc.
- FEI Number: 1000519239
- City: Torrance
- State: California
- Country Name: United States
- Address Line 1: 365 Maple Ave
- Zip Code: 90503
- Business Operations: API MANUFACTURE

## Related Documents

- [483 - PolyPeptide Laboratories, Inc. - 2024-05-10](https://www.keypedia.com/records/483/polypeptide-laboratories-inc/ba06b162-f067-4036-abb1-01c2e728f3fa) — source: FDA, date: May 10, 2024
- [FDA Inspection 1246171 - PolyPeptide Laboratories, Inc. - 2024-05-10](https://www.keypedia.com/records/fda_inspections/polypeptide-laboratories-inc/f50ba29e-e3b8-44a9-a050-0b7c0ebf6f77) — classification: Voluntary Action Indicated (VAI), source: FDA, date: May 10, 2024
- [FDA Inspection 1246171 - PolyPeptide Laboratories, Inc. - 2024-05-10](https://www.keypedia.com/records/fda_inspections/polypeptide-laboratories-inc/7ce2e271-d893-49fa-b550-a3e1ebd8df9c) — classification: Voluntary Action Indicated (VAI), source: FDA, date: May 10, 2024
- [EIR - PolyPeptide Laboratories, Inc. - 2021-11-19](https://www.keypedia.com/records/eir/polypeptide-laboratories-inc/19c17707-3c4a-4370-88b5-950e514b5073) — source: FDA, date: November 19, 2021
- [FDA Inspection 1159374 - PolyPeptide Laboratories, Inc. - 2021-11-19](https://www.keypedia.com/records/fda_inspections/polypeptide-laboratories-inc/5fd9ea50-9717-4d7a-be44-3fbd84c90649) — classification: No Action Indicated (NAI), source: FDA, date: November 19, 2021
- [FDA Inspection 1159374 - PolyPeptide Laboratories, Inc. - 2021-11-19](https://www.keypedia.com/records/fda_inspections/polypeptide-laboratories-inc/af021466-df72-405e-9b69-bdd15df330cb) — classification: No Action Indicated (NAI), source: FDA, date: November 19, 2021
- [483 - PolyPeptide Laboratories, Inc. - 2019-08-30](https://www.keypedia.com/records/483/polypeptide-laboratories-inc/b5e10f52-9c04-4a4d-8237-3a02d497c9b9) — source: FDA, date: August 30, 2019
- [FDA Inspection 1103072 - PolyPeptide Laboratories, Inc. - 2019-08-30](https://www.keypedia.com/records/fda_inspections/polypeptide-laboratories-inc/f8241a25-900b-41ee-ac9d-b8177058c42d) — classification: Voluntary Action Indicated (VAI), source: FDA, date: August 30, 2019
- [FDA Inspection 1021060 - PolyPeptide Laboratories, Inc. - 2017-07-19](https://www.keypedia.com/records/fda_inspections/polypeptide-laboratories-inc/bb82abf9-badf-4502-823c-de13bd77dffb) — classification: Voluntary Action Indicated (VAI), source: FDA, date: July 19, 2017
- [FDA Inspection 1021060 - PolyPeptide Laboratories, Inc. - 2017-07-19](https://www.keypedia.com/records/fda_inspections/polypeptide-laboratories-inc/ad3e102c-67c8-44cd-b715-6cb81268c9bb) — classification: Voluntary Action Indicated (VAI), source: FDA, date: July 19, 2017
- [FDA Inspection 953881 - PolyPeptide Laboratories, Inc. - 2015-12-03](https://www.keypedia.com/records/fda_inspections/polypeptide-laboratories-inc/60efef6c-d3a2-437f-a8d2-33c20dac1c21) — classification: No Action Indicated (NAI), source: FDA, date: December 3, 2015
- [FDA Inspection 953881 - PolyPeptide Laboratories, Inc. - 2015-12-03](https://www.keypedia.com/records/fda_inspections/polypeptide-laboratories-inc/d741dbc5-ed38-47f1-9fa7-51aa6f144e90) — classification: No Action Indicated (NAI), source: FDA, date: December 3, 2015
- [FDA Inspection 827287 - PolyPeptide Laboratories, Inc. - 2013-04-12](https://www.keypedia.com/records/fda_inspections/polypeptide-laboratories-inc/e8d21ab3-c9ec-48c5-b7e2-1919292fbc08) — classification: No Action Indicated (NAI), source: FDA, date: April 12, 2013

## Related Companies

- [Sigma-Aldrich Manufacturing LLC](https://www.keypedia.com/companies/sigma-aldrich-manufacturing-llc/e6637246-5655-4a30-849d-a25e3a5cd06c)
- [AmbioPharm, Inc](https://www.keypedia.com/companies/ambiopharm-inc/6a51f093-2f5b-433d-8e97-8e33820a50bf)
- [Kyongbo Pharmaceutical Co., Ltd.](https://www.keypedia.com/companies/kyongbo-pharmaceutical-co-ltd/6b8fd90f-4fa3-4c7b-9ed6-a8a8f4b511da)
- [Almac Sciences Limited](https://www.keypedia.com/companies/almac-sciences-limited/90ccdc83-facd-4798-aef2-460034d63adf)
- [MSD International GmbH](https://www.keypedia.com/companies/msd-international-gmbh/a9448cbd-d3cc-4427-a1d5-22dc511c3c07)
- [Signa S.A. de C.V.](https://www.keypedia.com/companies/signa-sa-de-cv/378a704e-5acb-49b8-9cd6-32503b29b3fc)
- [Jiangsu Jiaerke Pharmaceuticals Group Corp., Ltd.](https://www.keypedia.com/companies/jiangsu-jiaerke-pharmaceuticals-group-corp-ltd/7ccd91ae-2b6a-43f7-acc5-6c182cec0d11)
- [SAFC, Inc.](https://www.keypedia.com/companies/safc-inc/8b9b439f-c427-4b43-85d2-81ce982736be)
- [SCI Pharmtech Inc.](https://www.keypedia.com/companies/sci-pharmtech-inc/38edf740-19b5-4fbf-bd65-e8cd87a7b1db)
- [Partner Therapeutics Inc](https://www.keypedia.com/companies/partner-therapeutics-inc/837081c1-0ffa-4c06-94c1-4ce65e130882)

## Related Officers

- [https://www.fda.gov/media/120628/download](https://www.keypedia.com/people/santiago-gallardo-johnson/f5086b0c-c8fc-44dd-8d12-6506b9dd313f)
- [company_representative](https://www.keypedia.com/people/alexandra-limon/1a8f1851-33b8-4e50-b774-7b13bcb6fffa)
- [recipient](https://www.keypedia.com/people/timothy-f-culbreth/38e0baad-e35c-4528-bbc3-b43561c51c8d)
- [Chemist/Investigator - Pharmaceutical Quality](https://www.keypedia.com/people/walden-h-lee/18131eea-d1cb-47c4-af79-bea22d436031)
- [Regulatory Affairs Specialist](https://www.keypedia.com/people/andrew-le/573464c0-de29-4f64-ab33-62543b7fe719)